All In Biotech

Free tool

FAERS Monitor: Lamisil At

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021124 or its brand name (Lamisil At, Terbinafine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,412

Serious

890

63% of reports

Hospitalization

349

Death reported

54

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective121
  • pruritus87
  • rash82
  • nausea75
  • pain67
  • fatigue66
  • dyspnoea59
  • off label use59
  • diarrhoea53
  • ageusia51
  • headache50
  • weight decreased50
  • condition aggravated46
  • cough45
  • erythema44

Reports by year received

View as table
YearReports
20041
20051
20062
200730
200833
200920
201030
201126
201241
201316
201417
201558
201646
201755
201863
201980
202075
202186
2022155
2023154
2024173
2025160
202690

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,747 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ageusiaSignal5130.523.31,425
pruritusSignal873.42.8145
erythemaSignal443.22.465
rashSignal822.82.395
weight decreasedSignal502.72.051
coughSignal452.41.835
condition aggravatedSignal462.31.731
pain671.61.316
dyspnoea591.61.211
nausea751.41.19
drug ineffective1211.41.212
fatigue661.31.03
diarrhoea531.20.92
headache501.20.91
off label use591.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.